Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Gynecologic 5Breast 5CNS 4Myeloid 3Tumor-Agnostic 2Plasma cell 2Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1NET 1Endocrine 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ondansetron × Tumor-Agnostic × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Ohio State University Comprehensive Cancer Center

Phase NA Completed
40 enrolled 12 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡